Accessibility Menu
Foxo Technologies logo

Foxo Technologies(NYSEMKT) FOXO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-100%
1 Month+78%
N/A
Foxo Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.082026-08-31
Foxo Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.57%USD 0.072026-08-24
1 month+78.22%USD 0.052026-07-31
3 month-46.53%USD 0.152026-06-02
Year to date-73.27%USD 0.302025-12-31
1 year-99.61%USD 20.702025-08-29
3 year-100%USD 83,520.302023-09-01
5 year-100%USD 5,862,540.002021-08-10
Since inception-100%USD 5,970,505.702021-01-29

Foxo Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.86M

Net Income (TTM)

-$4.60M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 14, 2026

FOXO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Foxo Technologies

FOXO helps life insurers and healthcare providers use DNA science to improve services. Its saliva-based tests make health checks easier for patients and insurers. FOXO also supplies biological samples for research and runs rural hospitals and addiction treatment centers.

Products and Services

  • Healthcare Services: Runs rural hospitals and behavioral health centers, serving patients needing emergency care or addiction treatment.
  • Life Science Services: Supplies blood, tissue, and cell samples to research labs and pharmaceutical companies.
  • Labs: Offers saliva-based DNA tests for health and insurance, plus data analysis tools for interpreting genetic information.

Growth and Expansion

  • Acquired Myrtle Recovery Centers in June 2024, expanding behavioral health services.
  • Bought RCHI/Scott County Community Hospital in September 2024, adding rural hospital operations.
  • Purchased Vector BioSource in September 2025, entering biospecimen sourcing for research.
  • Expanded hospital services to include telemedicine and cardiac diagnostics, as announced in January 2026.
  • Developed international sourcing partnerships for biospecimens in 2025.

What Makes FOXO Stand Out

FOXO combines healthcare delivery, biospecimen sourcing, and DNA-based diagnostics under one roof. Its saliva-based DNA tests simplify health checks for insurers and patients. The company focuses on rural and underserved markets, using technology to streamline services.

Five Things You Need to Know

  • 2025 revenue was $16.4 million, up 304% from 2024.
  • Healthcare segment accounted for approximately 98% of 2025 revenue.
  • Net loss was $12.4 million in 2025, unchanged from 2024.
  • Working capital deficit reached $25.5 million at end of 2025.
  • Cash and cash equivalents were $0.2 million at end of 2025.

Bottom Line

FOXO has grown quickly by acquiring healthcare and research businesses. The company faces financial challenges but continues to diversify its services and technology offerings.

AI Generated • Apr 16, 2026

Industry

Software

Sector

Information Technology

Employees

5

CEO

Seamus Lagan

Website

www.foxotechnologies.com

Headquarters

West Palm Beach, FL 33401, US

FOXO Financials

Key Financial Metrics (TTM)

Gross Margin

47.49%

Operating Margin

-4.91%

Net Income Margin

-25.77%

Return on Equity

-43.80%

Return on Capital

-46.72%

Return on Assets

-10.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.48M

Operating Income

-$877.76K

EBITDA

-$470.25K

Operating Cash Flow

$355.81K

Capital Expenditure

-$147.12K

Free Cash Flow

$208.69K

Cash & ST Invst.

$58.41K

Total Debt

$20.04M

Foxo Technologies Performance Analysis

Foxo Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD -52,930,000145.2%
20232023-12-31USD 447,832N/A
20242024-12-31USD 4,019,176797.5%
20252025-12-31USD 16,408,863308.3%
Foxo Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-32.0%
Q42025-12-3124.9%
Q12026-03-3116.6%
Q22026-06-30-8.8%
Foxo Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5,015,188.1027.0%
20232023-12-31USD -422,394.82-91.6%
20242024-12-31USD -55,408.76-86.9%
20252025-12-31USD -397.02-99.3%
Foxo Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3031.0%
Q42025-12-3197.4%
Q12026-03-3193.3%
Q22026-06-3018100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$4.72M

-9.6%

Gross Profit

$2.32M

-28.5%

Gross Margin

49.20%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

230

N/A

Net Income

$8.14M

+1659.3%

EBITDA

$9.62M

+1429.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$58.41K

-81.8%

Total Debt

$20.04M

+32.9%

Accounts Receivable

$4.14M

-15.9%

Inventory

$160.47K

-3.4%

Long Term Debt

$2.87M

-16.6%

Short Term Debt

$17.16M

+47.5%

Return on Assets

-10.03%

N/A

Return on Invested Capital

-16.64%

N/A

Free Cash Flow

$302.67K

+112.7%

Operating Cash Flow

$298.67K

+112.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACONAclarion, Inc.
$2.35-2.08%
VRPXVirpax Pharmaceuticals, Inc.
$0.00+0.00%
PIIIP3 Health Partners Inc.
$9.06-1.74%
SLXNWSilexion Therapeutics Ltd.
$0.01-9.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About FOXO

What is the current price of Foxo Technologies?

Foxo Technologies is trading at N/A per share.

What is the 52-week range for Foxo Technologies?

Over the past 52 weeks, Foxo Technologies has traded between N/A and N/A.

How much debt does Foxo Technologies have?

As of the most recent reporting period, Foxo Technologies reported total debt of $20.65M.

How much cash does Foxo Technologies have on hand?

Foxo Technologies reported $58.41K in cash and cash equivalents in its most recent financial results.

What is Foxo Technologies’s dividend yield?

Foxo Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services